RARE
Ultragenyx Pharmaceutical Stock Analysis
AI Rating
- Quality0/10
- Growth↑ 5/10
- Value↓ 0/10
RARE Growth
- Revenue Y/Y↑ 8.63%
- EPS Y/Y↓ -3.92%
- FCF Y/Y↓ -27.44%
RARE Profitability
- Gross margin ↑ 83.50%
- EPS margin↓ -90.90%
- ROIC 5Y↓ -36.38%
RARE Risk
- Debt / Equity↓ 0.0
- Debt / FCF↓ 2.0
- Interest coverage↓ NA
Ultragenyx Pharmaceutical stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.